



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Doxorubicin hydrochloride (Standard)

Cat. No.:	HY-15142R
CAS No.:	25316-40-9
Molecular Formula:	C ₂₇ H ₃₀ ClNO ₁₁
Molecular Weight:	579.98
Target:	Autophagy; Apoptosis; HBV; HIV; AMPK; ADC Cytotoxin; Topoisomerase; Mitophagy; Bacterial; Antibiotic
Pathway:	Autophagy; Apoptosis; Anti-infection; Epigenetics; PI3K/Akt/mTOR; Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Doxorubicin (hydrochloride) (Standard) is the analytical standard of Doxorubicin (hydrochloride). This product is intended for research and analytical applications. Doxorubicin (Hydroxydaunorubicin) hydrochloride, a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC ₅₀ s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy ^{[1][2][3]} .
IC₅₀ & Target	IC ₅₀ : 0.8 μM (Topoisomerase I) ^[3] , 2.67 μM (Topoisomerase II) ^[1]

REFERENCES

- [1]. John L. Nitiss, et al. Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer*. 2009 May;9(5):338-50.
- [2]. Hee-Kyung Rhee, et al. Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones. *Bioorg Med Chem*. 2007 Feb 15;15(4):1651-8.
- [3]. P D Foglesong, et al. Doxorubicin inhibits human DNA topoisomerase I. *Cancer Chemother Pharmacol*. 1992;30(2):123-5.
- [4]. Nesstor Pilco-Ferreto, et al. Influence of doxorubicin on apoptosis and oxidative stress in breast cancer cell lines. *Int J Oncol*. 2016 Aug;49(2):753-62.
- [5]. Regine Lüpertz, et al. Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cells. *Toxicology*. 2010 May 27;271(3):115-21.
- [6]. Penelope D Ottewell, et al. Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. *J Natl Cancer Inst*. 2008 Aug 20;100(16):1167-78.
- [7]. Koda LY, Van der Kooy D. Doxorubicin: a fluorescent neurotoxin retrogradely transported in the central nervous system. *Neurosci Lett*. 1983 Mar 28;36(1):1-8. doi: 10.1016/0304-3940(83)90476-7. PMID: 6190113. 9
- [8]. Kauffman MK, Kauffman ME, Zhu H, Jia Z, Li YR. Fluorescence-Based Assays for Measuring Doxorubicin in Biological Systems. *React Oxyg Species (Apex)*. 2016;2(6):432-439. doi: 10.20455/ros.2016.873. PMID: 29707647; PMCID: PMC5921830.
- [9]. Mirza A Z, Shamshad H. Preparation and characterization of doxorubicin functionalized gold nanoparticles[J]. *European journal of medicinal chemistry*, 2011, 46(5): 1857-1860.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA